Noked Capital LTD bought a new stake in AbbVie Inc (NYSE:ABBV) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,900 shares of the company’s stock, valued at approximately $211,000.
Several other large investors have also recently modified their holdings of the company. Geode Capital Management LLC raised its position in shares of AbbVie by 5.3% during the fourth quarter. Geode Capital Management LLC now owns 17,582,527 shares of the company’s stock valued at $1,617,957,000 after buying an additional 880,288 shares during the last quarter. grace capital grew its position in AbbVie by 83.3% in the fourth quarter. grace capital now owns 5,500 shares of the company’s stock valued at $507,000 after purchasing an additional 2,500 shares in the last quarter. BT Wealth Management LLC bought a new position in AbbVie in the fourth quarter valued at $1,032,000. Nalls Sherbakoff Group LLC bought a new position in AbbVie in the fourth quarter valued at $83,000. Finally, Kaizen Advisory LLC grew its position in AbbVie by 8.9% in the fourth quarter. Kaizen Advisory LLC now owns 4,151 shares of the company’s stock valued at $383,000 after purchasing an additional 339 shares in the last quarter. Institutional investors own 68.15% of the company’s stock.
In related news, SVP Nicholas Donoghoe bought 7,525 shares of the stock in a transaction that occurred on Thursday, August 29th. The stock was purchased at an average cost of $66.19 per share, with a total value of $498,079.75. Following the purchase, the senior vice president now directly owns 13,090 shares of the company’s stock, valued at approximately $866,427.10. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jeffrey Ryan Stewart bought 15,552 shares of the stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average cost of $64.44 per share, with a total value of $1,002,170.88. Following the completion of the purchase, the senior vice president now directly owns 65,304 shares in the company, valued at $4,208,189.76. The disclosure for this purchase can be found here. Over the last three months, insiders acquired 143,077 shares of company stock worth $9,564,951. 0.08% of the stock is owned by corporate insiders.
NYSE:ABBV traded down $0.26 during trading hours on Wednesday, hitting $72.69. The company had a trading volume of 136,407 shares, compared to its average volume of 7,542,071. The company has a market capitalization of $107.03 billion, a PE ratio of 9.17, a price-to-earnings-growth ratio of 1.48 and a beta of 0.95. The stock has a 50-day moving average price of $67.35 and a 200 day moving average price of $74.34. AbbVie Inc has a 52 week low of $62.66 and a 52 week high of $96.60.
AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Friday, July 26th. The company reported $2.26 EPS for the quarter, beating the consensus estimate of $2.21 by $0.05. AbbVie had a negative return on equity of 182.70% and a net margin of 12.62%. The business had revenue of $8.26 billion during the quarter, compared to analyst estimates of $8.09 billion. During the same quarter last year, the firm posted $2.00 earnings per share. The company’s revenue for the quarter was down .3% on a year-over-year basis. On average, sell-side analysts forecast that AbbVie Inc will post 8.9 EPS for the current fiscal year.
The firm also recently disclosed a — dividend, which will be paid on Friday, November 15th. Shareholders of record on Tuesday, October 15th will be issued a $1.07 dividend. This represents a yield of 6.4%. The ex-dividend date is Friday, October 11th. AbbVie’s payout ratio is currently 54.11%.
AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc (NYSE:ABBV).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.